Longeveron (LGVN) Heart Treatment Falls Short. Can a Strategic Review Preserve Value?
Longeveron Inc. (NASDAQ:LGVN) reported on September 16 that ELPIS II, its randomized Phase 2b trial in 40 infants with hypoplastic left heart syndrome, missed its primary efficacy endpoint.




